IP Library Granted Patent US 10,004,685
Granted Patent B2
US 10,004,685 · App. 15/228,589 · Granted Jun 26, 2018

Ophthalmic emulsion

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,004,685
App. No.
15/228,589
Granted
Jun 26, 2018
Kind
B2
Abstract

The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Claims (18)

1. An ophthalmic emulsion, the emulsion comprising:

water forming an aqueous phase;

oil forming an oil phase;

a hydrophilic surfactant, wherein said hydrophilic surfactant is polyoxvethylene-40-stearate;

a hydrophobic surfactant, wherein said hydrophobic surfactant is sorbitan tristerate;

a charged phospholipid wherein the charged phospholipid is an anionic phospholipid named dimyristoyl phosphatidylglycerol and wherein the phospholipid is present in the emulsion in a concentration from about 0.05 to 7.0 percent by weight;

borate; and

a mucoadhesive galactomannan polymer selected from the group consisting of guar and hydroxvpropyl guar, and wherein the mucoadhesive galactomannan polymer is present in the emulsion at a concentration of at least about 0.01 w/v % but no greater than 1.0 w/v %;

wherein:

i. the oil phase is in droplets within the aqueous phase and the droplets have an average diameter that is no greater than about 1000 nm, but is at least 10 nm, wherein the average diameter is corresponding to 90% of the cumulative undersize distribution by volume measured using a Microtrac S3500 Particle Size Analyzer (Software Version 10.3.1);

and

ii. the borate and galactomannan polymer cooperatively act to form a gel upon instillation of the emulsion in an eye of an individual;

wherein said emulsion further comprises a polymeric quaternary ammonium compound as an anti-microbial preservative; and wherein said emulsion is free of a benzalkonium chloride.

2. The emulsion as in claim 1 wherein the oil is a hydrocarbon selected from mineral oil, paraffin oil and petrolatum.

3. The emulsion as in claim 1 wherein the oil is at least 0.1 w/v % and no greater than 5 w/v % of the emulsion.

4. The emulsion as in claim 1 wherein the hydrophilic surfactant is present in the emulsion in an amount that is at least 0.08 w/v % and is no greater than 0.8 w/v %.

5. The emulsion as in claim 1 wherein the hydrophobic surfactant is at least 0.01 w/v % and is no greater than 2.0 w/v %.

6. The emulsion as in claim 1 further comprising a borate/polyol buffer system.

Assignments (4)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 19, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051379/0438 →
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 18, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 051365/0048 →
MERGER Recorded Dec 16, 2019
From: ALCON RESEARCH, LTD.
To: ALCON RESEARCH, LLC
Reel/Frame 051294/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2018
From: KETELSON, HOWARD ALLEN; MEADOWS, DAVID L.
To: ALCON RESEARCH, LTD.
Reel/Frame 044830/0435 →